LA-19-0018
Proposes to allow the state to enter into a single, state-specific Supplemental Rebate Agreement (SRA) with drug manufacturer(s). The state will initially focus on providing an unlimited supply of HCV antiviral agent drugs, in exchange for the state paying a capped amount of money each year for these drugs.